Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
Immuneering Corporation - Class A (IMRX)
Company Research
Source: GlobeNewswire
- In Phase 2a arm investigating IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel, complete or partial responses have been observed in the first two patients (2/5) to date, for an initial response rate of 40% and an initial disease control rate of 80%, with all five patients continuing on treatment - - Initial data are at 240 mg QD (safety lead-in dose) of IMM-1-104; additional patients have now been dosed at 320 mg QD in this arm; IMM-1-104 has been well-tolerated to date in combination with gemcitabine/nab-paclitaxel - - Initial data are consistent with preclinical data presented at AACR, which demonstrated that IMM-1-104 combined with chemotherapy induced deeper responses than either agent alone - - Clear path forward expected for clinical development of IMM-1-104 in combination with gemcitabine/nab-paclitaxel for pancreatic cancer, assuming initial data is representative; FDA previously granted IMM-1-104 Fast Track designation for the treatment of first-
Show less
Read more
Impact Snapshot
Event Time:
IMRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMRX alerts
High impacting Immuneering Corporation - Class A news events
Weekly update
A roundup of the hottest topics
IMRX
News
- Immuneering Leads The Pack Of 3 US Penny Stocks To Monitor [Yahoo! Finance]Yahoo! Finance
- Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $13.00 price target on the stock.MarketBeat
- Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.MarketBeat
- Immuneering Reports Third Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswire
- Immuneering rises on orphan drug designation for treatment of pancreatic cancer [Seeking Alpha]Seeking Alpha
IMRX
Earnings
- 11/13/24 - Beat
IMRX
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/13/24 - Form 10-Q
- IMRX's page on the SEC website